Who Owns ACADIA Pharmaceuticals Inc
Every manager with more than $100m in listed equities files a 13F each quarter naming what they hold. These are the ones reporting a position in ACADIA Pharmaceuticals Inc.
Who crossed 5% of ACAD →Positions as of 2026-09-30
Largest first. The move is against the previous quarter that manager filed, not the previous calendar quarter.
| Manager | Value |
|---|---|
| Gradient Investments LLCCOM31.6K shtrimmed | $636.6K |
| Valeo Financial Advisors, LLCStock21K sh— | $423.8K |
| Farther Finance Advisors, LLCStock9K shadded | $181.8K |
| GAMMA Investing LLCCommon Stock4.1K shadded | $81.9K |
| Grove Bank & TrustCOM200 shheld | $4K |
| MassMutual Private Wealth & Trust, FSBCommon / Ordinary Stock62 shheld | $1.2K |
| Marquette Asset Management, LLCCOM42 shheld | $847 |
| GILPIN WEALTH MANAGEMENT, LLCCOM19 shheld | $383 |
| Davis Capital ManagementStock12 shadded | $242 |
Source: quarterly 13F filings, via EDGAR. A 13F reports positions by CUSIP alone; each CUSIP here has been confirmed against OpenFIGI rather than matched by name, because a name match would attribute one company's shareholders to another. Positions are as of quarter end and can be months old by the time they are filed, and 13F covers long equity positions only — not shorts, and not most debt. The summed value is what these filers reported, not the company's institutional ownership.
More on ACAD
Follow ACADIA Pharmaceuticals Inc (ACAD) by email
New trades in ACADIA Pharmaceuticals Inc (ACAD) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.